![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Fast Track Designation to Innocrin Pharmaceuticals’ Seviteronel
FDA Grants Fast Track Designation to Innocrin Pharmaceuticals’ Seviteronel
April 10, 2017
Innocrin Pharmaceuticals has received its second fast track designation for seviteronel (VT-464).
The new designation is for the treatment of women with advanced androgen receptor-positive triple-negative breast cancer and women or men with advanced estrogen receptor-positive breast cancer.
Seviteronel selectively inhibits CYP17 lyase, an enzyme needed for the synthesis of androgens and estrogens, and also directly blocks the receptor.
Seviteronel is a once-daily oral therapeutic given without prednisone.
Upcoming Events
-
21Oct